DDInter1261 DDInter1435
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neratinib
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Conivaptan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Stiripentol
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Naloxegol may lead to a major life threatening interaction when taken with Conivaptan
Naloxegol may lead to a major life threatening interaction when taken with Stiripentol